TITLE

Posttransplantation thrombotic thrombocytopenic purpura: a single-center experience and a contemporary review

AUTHOR(S)
Elliott, Michelle A.; Nichols Jr., William L.; Plumhoff, Elizabeth A.; Ansell, Stephen M.; Dispenzieri, Angela; Gastineau, Dennis A.; Gertz, Morie A.; Inwards, David J.; Lacy, Martha Q.; Micallef, Ivana N.M.; Tefferi, Ayalew; Litzow, Mark R.; Nichols, William L Jr; Litzow, Mark
PUB. DATE
April 2003
SOURCE
Mayo Clinic Proceedings;Apr2003, Vol. 78 Issue 4, p421
SOURCE TYPE
Academic Journal
DOC. TYPE
journal article
ABSTRACT
Objective: To assess the activity of von Willebrand factor-cleaving protease (vWF-CP) in patients with thrombotic thrombocytopenic purpura (TTP) complicating bone marrow transplantation (BMT) and peripheral blood stem cell transplantation (PBSCT).Patients and Methods: From March 1, 1999, to June 30, 2001, allogeneic and autologous hematopoietic stem cell transplantation was performed in 118 and 400 patients, respectively. We reviewed risk factors for development of posttransplantation TTP and measured vWF-CP activity during active TTP in 10 recipients.Results: The incidence of TTP after allogeneic and autologous transplantation was 6.8% (8/118) and 0.25% (1/400), respectively. Among the allogeneic transplant recipients, the incidence of TTP after nonmyeloablative (NMA) PBSCT, matched unrelated donor BMT, and sibling BMT or PBSCT was 15.4% (2/13), 11.8% (2/17), and 4.5% (4/88), respectively. Of the 10 patients with TTP, 9 (90%) had received extensive prior therapy, including autologous transplantation in both NMA recipients. Acute graft-vs-host disease (GVHD) prophylaxis consisted of cyclosporine and methotrexate in most affected patients. The vWF antigen level was elevated in all patients, and no patients showed evidence of vWF-CP deficiency. During active TTP, 6 patients had grade II-IV acute GVHD, 1 had extensive chronic GVHD, and 4 had cytomegalovirus viremia. Risk factor analysis for development of TTP showed that transplant type (NMA and matched unrelated donor) and source of stem cells (bone marrow vs peripheral blood stem cell) were significant.Conclusions: Posttransplantation TTP was not found to be associated with severe vWF-CP deficiency. The elevated levels of vWF antigen are consistent with diffuse endothelial injury likely because of multiple interacting factors such as extensive prior therapy, GVHD, cyclosporine, and reactivation of cytomegalovirus. The disorder appears to be more frequent among patients with, or at risk for, acute GVHD, suggesting a possible role in the pathogenesis. Nonmyeloablative transplantation does not appear to confer a lesser risk, possibly for these reasons.
ACCESSION #
9763721

 

Related Articles

  • Thrombotic microangiopathy following organ transplantation. Ruggenenti, Piero // Kidney International;May2003, Vol. 63 Issue 5, p1959 

    Responds to Phuong-Thu T. Pham and colleagues' comments on the authors' article regarding thrombotic microangiopathy (TMA) following organ transplantation. Forms of TMA; Criteria for administering plasma therapy to patients with TMA; Deficiency of von Willebrand factor-cleaving protease activity.

  • Thrombotic microangiopathy following organ transplantation. Pham, Phuong-Thu T.; Pham, Phuong-Chi T.; Wilkinson, Alan H. // Kidney International;May2003, Vol. 63 Issue 5, p1959 

    Comments on Piero Ruggenenti's article regarding thrombotic microangiopathy (TMA) following organ transplantation. Deficiency of von Willebrand factor-cleaving protease activity; Efficacy of plasma therapy against TMA.

  • Staged Hand-Assisted Bilateral Native Nephrectomy for Management of Posttransplant Polyuria in an Adult with Dent’s Disease. Montero, Rosa M.; Hilton, Rachel; Olsburgh, Jonathon // Case Reports in Transplantation;1/11/2015, Vol. 2015, p1 

    Polyuria after kidney transplantation causes graft dysfunction and increased thrombotic risk. We present a case of a polyuric adult with Dent’s disease who underwent staged bilateral native nephrectomies, the first operation before transplant and the second four months after transplant....

  • Catastrophic antiphospholipid syndrome complicating orthotopic liver transplantation. Villamil, A; Sorkin, E; Basta, M C; Mysler, E; Macias, S; Pekolj, J; Ciardullo, M; Eleta, F; de Santiba�es, E; Allievi, A; Gadano, A // Lupus;2003, Vol. 12 Issue 2, p140 

    Catastrophic antiphospholipid syndrome (CAPS) is an acutely devastating situation characterized by widespread thrombotic microangiopathy in the presence of elevated titers of antiphospholipid antibodies. We describe a 57-year old woman who underwent liver transplantation for primary sclerosing...

  • Pericardial effusion in pediatric SCT recipients with thrombotic microangiopathy. Lerner, D; Dandoy, C; Hirsch, R; Laskin, B; Davies, S M; Jodele, S // Bone Marrow Transplantation;Jun2014, Vol. 49 Issue 6, p862 

    A letter to the editor is presented regarding pericardial effusion (PEF), which is a complication of hematopoietic stem cells transplantation (HSCT) in pediatric recipients with thrombotic microangiopathy.

  • Oligotide, a defibrotide derivative, protects human microvascular endothelial cells against fludarabine-induced activation, damage and allogenicity. Eissner, G; Iacobelli, M; Blüml, S; Burger, V; Haffner, S; Andreesen, R; Holler, E // Bone Marrow Transplantation;May2005, Vol. 35 Issue 9, p915 

    Summary:Fludarabine is a nonmyeloablative immunosuppressant increasingly used as a component of alternative reduced-intensity conditioning regimens prior to allogeneic stem cell transplantation (SCT). However, we have previously shown that 2-fluoroadenine 9-beta-D-arabinofuranoside (F-Ara) as...

  • Counting the cost: markers of endothelial damage in hematopoietic stem cell transplantation. Woywodt, A.; Haubitz, M.; Buchholz, S.; Hertenstein, B. // Bone Marrow Transplantation;Dec2004, Vol. 34 Issue 12, p1015 

    Summary:During hematopoietic stem cell transplantation (HSCT), endothelial damage is the pathological hallmark of veno-occlusive disease of the liver, thrombotic microangiopathy, capillary leak syndrome and graft-versus-host disease. Events prior to conditioning, the conditioning regimen itself...

  • Comparison of thrombotic microangiopathy after allogeneic hematopoietic cell transplantation with high-dose or nonmyeloablative conditioning. Willems, E.; Baron, F.; Seidel, L.; Frère, P.; Fillet, G.; Beguin, Y. // Bone Marrow Transplantation;Apr2010, Vol. 45 Issue 4, p689 

    The role of conditioning intensity on occurrence of thrombotic microangiopathy (TMA) after allogeneic hematopoietic cell transplantation (HCT) has remained unclear thus far. Here, we retrospectively compared the incidence of TMA in patients given allogeneic hematopoietic stem cells after either...

  • Hematopoietic stem cell transplantation-associated thrombotic microangiopathy: defining a disorder. George, J. N. // Bone Marrow Transplantation;Jun2008, Vol. 41 Issue 11, p917 

    The author reflects on the importance of hematopoietic stem cell transplantation-associated thrombotic microangiopathy (TA-TMA). He remarks that TA-TMA's importance is documented not only by the experience of clinicians but also by extensive clinical investigation. He asserts that despite...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics